4D Molecular Therapeutics, Inc. 8-K

What Happened
4D Molecular Therapeutics, Inc. announced on June 24, 2026 that it entered into a Loan and Security Agreement with Hercules Capital providing for senior secured term loans of up to $200.0 million. The facility matures June 1, 2031. The company drew a Tranche 1A loan of $20.0 million at closing; additional tranches are available subject to the company’s election, achievement of development milestones, or Hercules’ discretion.

Key Details

• Tranches: Tranche 1A $20.0M (drawn), Tranche 1B $30.0M (available to June 15, 2027), Tranche 2A $12.5M, Tranche 2B $12.5M, Tranche 3 $50.0M, Tranche 4 $25.0M (milestone‑based), Tranche 5 $50.0M (Hercules’ discretion).
• Interest & fees: Tranche 1A interest = greater of prime + 2.00% or 8.75%; other tranches = greater of prime + 2.50% or 9.25%; initial facility charge $500,000; 1.00% tranche facility charge for Tranches 2–5.
• Security & guarantees: Obligations are secured by substantially all of the company’s assets, including intellectual property; future subsidiaries may be required to guarantee and pledge assets.
• Covenants & tests: Includes minimum cash covenants (tested when borrowings exceed $25M or $50M under certain conditions), and a performance covenant tested nine months after FDA approval and once borrowings reach $75M (tests include market cap, cash‑to‑debt ratios, or trailing product revenue). Events of default permit acceleration of obligations; insolvency events trigger automatic acceleration.

Why It Matters
This agreement provides 4D with up to $200M of committed debt financing and an immediate $20M draw, which can support operations and development milestones. However, the loans are senior secured and pledge substantially all assets (including IP), and include cash‑ and performance‑based covenants that could affect the company’s financial flexibility. Investors should weigh the added liquidity against the secured nature of the debt and the covenant triggers tied to future borrowing levels and product approval/revenue milestones.